Literature DB >> 3821824

Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.

M I Kaiser-Kupfer, L Fujikawa, T Kuwabara, S Jain, W A Gahl.   

Abstract

In patients with nephropathic cystinosis, corneal crystals develop by one year of age; they progressively accumulate and eventually cause recurrent corneal erosions and photophobia. After an in vitro study of cystinotic corneal stromal cells showed cystine depletion by cysteamine and after topical cysteamine was determined to be nontoxic in rabbits, we performed a controlled double-blind clinical trial of 10 mM cysteamine eyedrops in young patients with cystinosis, using one eye for treatment and the other as the control. Two children begun on the protocol before two years of age had a striking decrease in the number of corneal crystals in the cysteamine-treated eye within four to five months of entering the study. Cysteamine eyedrops appear to be safe and efficacious in the short-term treatment of patients with cystinosis who are under two years of age. The long-term value of such treatment and its effectiveness in older patients remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3821824     DOI: 10.1056/NEJM198703263161304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  25 in total

Review 1.  The differential diagnosis of crystals in the retina.

Authors:  F Nadim; H Walid; J Adib
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

3.  Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.

Authors:  N P Jones; R J Postlethwaite; J L Noble
Journal:  Br J Ophthalmol       Date:  1991-05       Impact factor: 4.638

4.  A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis.

Authors:  E T Tsilou; D Thompson; A S Lindblad; G F Reed; B Rubin; W Gahl; J Thoene; M Del Monte; J A Schneider; D B Granet; M I Kaiser-Kupfer
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

Review 5.  Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature.

Authors:  Ekaterini Tsilou; Min Zhou; William Gahl; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 6.048

6.  Crystalline keratopathy in nephropathic cystinosis.

Authors:  Girish Chandra Bhatt; Amber Kumar; Brijesh Takkar
Journal:  Sudan J Paediatr       Date:  2019

Review 7.  Update on nephropathic cystinosis.

Authors:  J A Schneider; B Katz; R B Melles
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

8.  The promoter of a lysosomal membrane transporter gene, CTNS, binds Sp-1, shares sequences with the promoter of an adjacent gene, CARKL, and causes cystinosis if mutated in a critical region.

Authors:  C Phornphutkul; Y Anikster; M Huizing; P Braun; C Brodie; J Y Chou; W A Gahl
Journal:  Am J Hum Genet       Date:  2001-08-14       Impact factor: 11.025

9.  Effect of Storage Conditions on Stability of Ophthalmological Compounded Cysteamine Eye Drops.

Authors:  Ahmed Reda; Ann Van Schepdael; Erwin Adams; Prasanta Paul; David Devolder; Mohamed A Elmonem; Koenraad Veys; Ingele Casteels; Lambertus van den Heuvel; Elena Levtchenko
Journal:  JIMD Rep       Date:  2017-12-07

Review 10.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.